National depressive and manic-depressive association consensus statement on the use of placebo in clinical trials of mood disorders ARCHIVES OF GENERAL PSYCHIATRY Charney, D. S., Nemeroff, C. B., Lewis, L., Laden, S. K., Gorman, J. M., Laska, E. M., Borenstein, M., Bowden, C. L., Caplan, A., Emslie, G. J., Evans, D. L., Geller, B., Grabowski, L. E., Herson, J., Kalin, N. H., Keck, P. E., Kirsch, I., Krishnan, K. R., Kupfer, D. J., Makuch, R. W., Miller, F. G., Pardes, H., Post, R., Reynolds, M. M., Roberts, L., Rosenbaum, J. F., Rosenstein, D. L., Rubinow, D. R., Rush, A. J., Ryan, N. D., Sachs, G. S., Schatzberg, A. F., Solomon, S. 2002; 59 (3): 262-270


A consensus conference on the use of placebo in mood disorder studies consisted of expert presentations on bioethics, biostatistics, unipolar depression, and bipolar disorder. Work groups considered evidence and presented statements to the group. Although it was not possible to write a document for which there was complete agreement on all issues, the final document incorporated input from all authors. There was consensus that placebo has a definite role in mood disorder studies. Findings of equivalence between a new drug and standard treatment in active control studies is not evidence of efficacy unless the new drug is also significantly more effective than placebo. Add-on studies in which patients are randomized to standard therapy plus the investigational drug or standard therapy plus placebo are especially indicated for high-risk patients. Mood disorders in elderly and pediatric patients are understudied, and properly designed trials are urgently needed. Research is needed on the ethical conduct of studies to limit risks of medication-free intervals and facilitate poststudy treatment. Patients must fully understand the risks and lack of individualized treatment involved in research.

View details for Web of Science ID 000174300800007

View details for PubMedID 11879164